Evotec SE ADR Market Cap ($1.15 Billion)
Market Cap & Net Worth: Evotec SE ADR (EVO)
Evotec SE ADR market cap. Evotec SE ADR (NASDAQ:EVO) has a market capitalization of $1.15 Billion ($1.15 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8085 globally and #2414 in its home market, demonstrating a 0.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evotec SE ADR's stock price $3.23 by its total outstanding shares 355209170 (355.21 Million). Also see cash efficiency ratio of Evotec SE ADR for how efficiently the company converts equity into cash flow.
Evotec SE ADR Market Cap History (2015–2026)
Evotec SE ADR market cap history from 2015 to 2026. Data shows growth from $801.88 Million to $557.68 Million (3.69% CAGR). Check Evotec SE ADR (EVO) stock price for real-time trading data and today's change.
Index Memberships
Evotec SE ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.04% | #237 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #892 of 3165 |
Weight: Evotec SE ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Evotec SE ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evotec SE ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Evotec SE ADR annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.44x
Evotec SE ADR's market cap is 1.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.38 Billion | $164.51 Million | $27.53 Million | 8.40x | 50.22x |
| 2017 | $2.85 Billion | $257.63 Million | $24.26 Million | 11.06x | 117.51x |
| 2018 | $3.54 Billion | $375.40 Million | $84.17 Million | 9.42x | 42.02x |
| 2019 | $4.56 Billion | $446.44 Million | $38.16 Million | 10.22x | 119.63x |
| 2020 | $6.52 Billion | $500.92 Million | $6.28 Million | 13.01x | 1038.10x |
| 2021 | $8.44 Billion | $618.03 Million | $215.51 Million | 13.65x | 39.15x |
| 2022 | $2.87 Billion | $751.45 Million | -$175.66 Million | 3.82x | N/A |
| 2023 | $4.17 Billion | $781.43 Million | -$83.91 Million | 5.33x | N/A |
| 2024 | $1.48 Billion | $796.97 Million | -$196.08 Million | 1.85x | N/A |
| 2025 | $1.09 Billion | $757.26 Million | -$99.43 Million | 1.44x | N/A |
Competitor Companies of EVO by Market Capitalization
Companies near Evotec SE ADR in the global market cap rankings as of November 5, 2026. Also see Evotec SE ADR (EVO) total assets for a full breakdown of the balance sheet.
Key companies related to Evotec SE ADR by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Evotec SE ADR (2015–2026)
Market capitalization of Evotec SE ADR from 2015 to today. Between 2015 and today, Evotec SE ADR's market cap moved from $801.88 Million to $ 557.68 Million, with a yearly change of 3.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $557.68 Million | -49.03% |
| 2025 | $1.09 Billion | -25.96% |
| 2024 | $1.48 Billion | -64.54% |
| 2023 | $4.17 Billion | +44.99% |
| 2022 | $2.87 Billion | -65.94% |
| 2021 | $8.44 Billion | +29.45% |
| 2020 | $6.52 Billion | +42.78% |
| 2019 | $4.56 Billion | +29.05% |
| 2018 | $3.54 Billion | +24.08% |
| 2017 | $2.85 Billion | +106.17% |
| 2016 | $1.38 Billion | +72.43% |
| 2015 | $801.88 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Evotec SE ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.15 Billion USD |
| MoneyControl | $1.15 Billion USD |
| MarketWatch | $1.15 Billion USD |
| marketcap.company | $1.15 Billion USD |
| Reuters | $1.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more